Investigação clínica com microdoses de canabinóides para tratamento da Doença de Alzheimer
Description
Alzheimer's disease (AD) is closely linked to the accumulation of neurotoxins derived from Aβ and tau, as well as cognitive impairment. The premise of this project is that the imbalance in the endocannabinoid system occurs in an AD-dependent manner. The connection between dementia, inflammation, Aβ, and changes in the cannabinoid system in experimental AD models has been reported. Cannabinoid microdoses may restore baseline brain function while avoiding major side effects. Despite extensive research on new AD therapies, no significant improvement has been achieved recently, and there is virtually no consensus on how scientists will innovate to shed light on a new treatment. Currently, there are no published studies examining the effect of microdoses on human AD pathology. Cannabinoid-based therapy has emerged as crucial for treating many diseases considered incurable. The expected results of this project will provide important information on the ability of cannabinoid microdoses to offset neurochemical imbalances during AD progression, thus improving memory performance, as well as how they may affect inflammation, Aβ levels, and tau. The key point is to provide evidence that cannabinoid microdoses can serve as an effective treatment for AD while avoiding major side effects. The goal of this project is to determine the effect of cannabinoid microdoses in AD patients, with the aim of evaluating memory and cognition, assessing cerebral blood perfusion, and verifying proteins relevant to inflammation and progression associated with AD. The results are expected to establish that cannabinoid microdoses are essential to restore the baseline function of the endocannabinoid system in AD-affected brains and their beneficial effects. This project may be instrumental in validating new therapeutic approaches for AD.